Opus Genetics (IRD) – Investment Analysts’ Weekly Ratings Changes

Opus Genetics (NASDAQ: IRD) recently received a number of ratings updates from brokerages and research firms:

• 7/6/2026 – Opus Genetics had its “buy” rating reaffirmed by Chardan Capital. They now have a $13.00 price target on the stock.
• 7/6/2026 – Opus Genetics had its “buy” rating reaffirmed by BTIG Research. They now have a $12.00 price target on the stock.
• 6/23/2026 – Opus Genetics is now covered by Royal Bank Of Canada. They set an “outperform” rating and a $10.00 price target on the stock.
• 6/23/2026 – Opus Genetics is now covered by Royal Bank Of Canada. They set a “moderate buy” rating and a $10.00 price target on the stock.
• 6/18/2026 – Opus Genetics had its price target raised by Chardan Capital from $11.00 to $13.00. They now have a “buy” rating on the stock.
• 6/17/2026 – Opus Genetics was upgraded by Chardan Capital to “strong-buy”.
• 6/17/2026 – Opus Genetics had its “buy” rating reaffirmed by HC Wainwright. They now have a $8.00 price target on the stock.
• 6/16/2026 – Opus Genetics had its “buy” rating reaffirmed by BTIG Research. They now have a $12.00 price target on the stock.
• 6/15/2026 – Opus Genetics had its “market outperform” rating reaffirmed by Citizens Jmp. They now have a $11.00 price target on the stock.
• 6/10/2026 – Opus Genetics was upgraded by Zacks Research from “strong sell” to “hold”.
• 6/4/2026 – Opus Genetics is now covered by Guggenheim. They set a “buy” rating and a $16.00 price target on the stock.
• 6/4/2026 – Opus Genetics is now covered by Guggenheim. They set a “buy” rating and a $16.00 price target on the stock.
• 5/21/2026 – Opus Genetics is now covered by Leerink Partners. They set an “outperform” rating and a $10.00 price target on the stock.
• 5/16/2026 – Opus Genetics was downgraded by Wall Street Zen from “hold” to “sell”.
• 5/13/2026 – Opus Genetics had its price target lowered by Citizens Jmp from $12.00 to $11.00. They now have a “market outperform” rating on the stock.
• 5/12/2026 – Opus Genetics was downgraded by Zacks Research from “hold” to “strong sell”.

Insider Buying and Selling at Opus Genetics

In related news, Director Fighting Blindness Foundation sold 1,700,000 shares of the stock in a transaction on Monday, May 18th. The shares were sold at an average price of $4.35, for a total transaction of $7,395,000.00. Following the sale, the director directly owned 3,792,171 shares of the company’s stock, valued at approximately $16,495,943.85. This represents a 30.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO George Magrath sold 9,511 shares of the stock in a transaction on Thursday, April 23rd. The stock was sold at an average price of $5.22, for a total transaction of $49,647.42. Following the sale, the chief executive officer directly owned 1,741,344 shares in the company, valued at $9,089,815.68. This trade represents a 0.54% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 1,738,703 shares of company stock worth $7,596,606. 11.70% of the stock is currently owned by insiders.

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.